Note 12 - Segment Information (Tables)

12 Months Ended

Jun. 30, 2021

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Year Ended June 30,
	2021			2020			2019
Net sales:
Protein Sciences	$	704,564		$	555,352		$	543,159
Diagnostics and Genomics		227,744			184,549			171,674
Intersegment		(1,276	)		(1,210	)		(827	)
Consolidated net sales	$	931,032		$	738,691		$	714,006
Operating Income:
Protein Sciences	$	328,837		$	234,929		$	240,919
Diagnostics and Genomics		38,425			14,965			10,079
Segment operating income		367,262			249,894			250,998
Costs recognized upon sale of acquired inventory		(1,565	)		-			(3,739	)
Amortization of acquired intangible assets		(64,239	)		(60,865	)		(58,550	)
Gain on escrow settlement		-			7,169			-
Acquisition related expenses		(7,114	)		(416	)		(2,282	)
Restructuring costs		(142	)		(87	)		-
Stock-based compensation, inclusive of employer taxes		(51,846	)		(34,262	)		(33,057	)
Corporate general, selling and administrative expenses		(5,060	)		(4,015	)		(6,651	)
Consolidated operating income	$	237,296		$	157,419		$	146,719

	Year Ended June 30,
	2021		2020		2019
Consumables revenue - Protein Sciences	$	557,037	$	431,052	$	430,655
Consumables revenue - Diagnostics and Genomics		194,948		171,590		158,324
Total consumable revenue	$	751,985	$	602,642	$	588,979

	Year ended June 30,
Long-lived assets:	2021		2020
United States and Canada	$	190,501	$	162,039
Europe		13,949		13,120
Asia		3,457		1,670
Total long-lived assets	$	207,907	$	176,829
Intangible assets:
United States and Canada	$	594,512	$	499,875
Europe		9,369		12,349
Asia		12,087		4,321
Total intangible assets	$	615,968	$	516,545